Thus, in this study, we recruited participants with various CLDs, cirrhosis secondary to these CLDs, and healthy controls to compare asprosin levels across the three groups, and further explored the relationships between asprosin and markers of liver fibrosis as well as various metabolic parameters. This evidence concerns the gene FBN1 and Hepatic fibrosis.